David Lamond, Director at Quince Therapeutics, Inc. (QNCX), bought 67,881 shares at $1.04 ($69K) on 2023-12-14, disclosed to the SEC on 2023-12-14.
Open-market purchase of $69k QNCX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.00 | 300 | $300 | 0.4% |
| 2 | $1.02 | 22,327 | $23K | 32.9% |
| 3 | $1.00 | 22,627 | $23K | 32.7% |
| 4 | $1.04 | 22,627 | $24K | 34.0% |
| Total | $1.02 avg | 67,881 | $69K | 100% |
| Filing → |
| QNCX | BUY | 2023-08-31 | $216K | — | Filing → |
| QNCX | BUY | 2023-08-17 | $620K | — | Filing → |
| AMTI | BUY | 2022-05-23 | $211K | — | Filing → |